122 related articles for article (PubMed ID: 32466563)
1. Paclitaxel and Sorafenib: The Effective Combination of Suppressing the Self-Renewal of Cancer Stem Cells.
Nawara HM; M Afify S; Hassan G; Zahra MH; Atallah MN; Mansour H; Abu Quora HA; Alam MJ; Osman A; Kakuta H; Hamada H; Seno A; Seno M
Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466563
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer.
Choi KH; Jeon JY; Lee YE; Kim SW; Kim SY; Yun YJ; Park KC
Transl Oncol; 2019 Feb; 12(2):381-388. PubMed ID: 30522045
[TBL] [Abstract][Full Text] [Related]
3. Diphenyleneiodonium efficiently inhibits the characteristics of a cancer stem cell model derived from induced pluripotent stem cells.
Monzur S; Hassan G; Afify SM; Kumon K; Mansour H; Nawara HM; Sheta M; Abu Quora HA; Zahra MH; Xu Y; Fu X; Seno A; Wikström P; Szekeres FLM; Seno M
Cell Biochem Funct; 2022 Apr; 40(3):310-320. PubMed ID: 35285948
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
Zou H; Cao X; Xiao Q; Sheng X; Ren K; Quan M; Song Z; Li D; Zheng Y; Zeng W; Cao J; Peng Y
Oncol Rep; 2016 Sep; 36(3):1731-8. PubMed ID: 27461522
[TBL] [Abstract][Full Text] [Related]
5. [Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
Li N; Zhang Y; Wu T; Li M
Ai Zheng; 2009 Aug; 28(8):838-43. PubMed ID: 19664330
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
10. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
[TBL] [Abstract][Full Text] [Related]
11. JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.
Wang C; Wang R; Zhou K; Wang S; Wang J; Shi H; Dou Y; Yang D; Chang L; Shi X; Liu Y; Xu X; Zhang X; Ke Y; Liu H
Cancer Chemother Pharmacol; 2016 Nov; 78(5):971-982. PubMed ID: 27620208
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma.
Yang X; Xia W; Chen L; Wu CX; Zhang CC; Olson P; Wang XQ
Oncotarget; 2018 Oct; 9(79):34996-35007. PubMed ID: 30405889
[TBL] [Abstract][Full Text] [Related]
13. Novel Combination of Mesenchymal Stem Cell-Conditioned Medium with Sorafenib Have Synergistic Antitumor Effect of Hepatocellular Carcinoma Cells.
Seyhoun I; Hajighasemlou S; Ai J; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Parseh B; Abdolahi S; Ghazvinian Z; Shadnoush M; Verdi J
Asian Pac J Cancer Prev; 2019 Jan; 20(1):263-267. PubMed ID: 30678447
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Murray A; Little SJ; Stanley P; Maraveyas A; Cawkwell L
Oncol Rep; 2010 Oct; 24(4):1049-58. PubMed ID: 20811688
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Berruti A; Sperone P; Ferrero A; Germano A; Ardito A; Priola AM; De Francia S; Volante M; Daffara F; Generali D; Leboulleux S; Perotti P; Baudin E; Papotti M; Terzolo M
Eur J Endocrinol; 2012 Mar; 166(3):451-8. PubMed ID: 22189997
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy-Refractory Testicular Tumors.
Lian B; Zhang W; Wang T; Yang Q; Jia Z; Chen H; Wang L; Xu J; Wang W; Cao K; Gao X; Sun Y; Shao C; Liu Z; Li J
Oncologist; 2019 Dec; 24(12):e1437-e1442. PubMed ID: 31492770
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
20. Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Pennarun B; Kleibeuker JH; Boersma-van Ek W; Kruyt FA; Hollema H; de Vries EG; de Jong S
J Pathol; 2013 Feb; 229(3):410-21. PubMed ID: 23132258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
